Our product delivers pharmaceuticals – vaccines and drugs - through the skin. We accomplish this using jet injection technology. We do not use needles – big or small, or patches of any kind.
Our needle-free delivery device is FDA cleared for marketing. It can deliver 0.5 ml of a liquid medication through the skin of the arm, the abdomen or the thigh, into the muscle (intramuscular or IM area) where many vaccines are routinely delivered, or into the subcutaneous layer or SC depth between the skin and muscle, where insulin is injected. In fact PharmaJet can be used to inject just about any licensed injectable liquid medicine like vaccines for flu, and drugs like generic sumatriptan and women’s reproductive hormones to treat infertility.
We have a pipeline of new products underway. A 0.1 ml device is under development for intradermal delivery into the 2 mm upper layer of the skin where the immune system is very active. Another product, providing a variable volume between 0.1 and 1.0 ml is underway for drug delivery.
Our mission to serve the global community is shared by employees and investors. We want fewer needle injections because it means a safer work place with less exposure to needle stick injuries, reduces the amount of hazardous sharps medical waste and provides better control over the spread of blood borne HIV and hepatitis from needle reuse.
We would like to help children avoid needle jabs when bravely taking their childhood vaccinations and booster shots. We also serve their pediatricians, and nurses who give the shots, and tens of millions of "belenophobics" who until now have had no practical recourse to their fear of needles.
We are a young start-up with a better jet injector. Our opportunity to serve individual patients and also public health needs worldwide is enormous. If you share our mission and are interested in working here, collaborating with us, or purchasing our device, then please contact us. We are located in Denver, Colorado, San Francisco, California and Baltimore, Maryland.
Ron Bauer, Executive Director of Quality, Regulatory Affairs and Manufacturing. 25 years of engineering, Quality Systems, and Regulatory Affairs management, at MedSource, Honeywell and Aspen Laboratories. Manages PharmaJet's regulatory clearances, and ISO compliance. BS in engineering from Metropolitan State College.
John Bingham, Design and Production Engineering Chief. 20 years of experience in industrial design, mold design, product development, rapid prototyping and manufacturing, owned and managed two injection molding companies. Holds several patents.
Craig Jack, Vice President, Operations and Strategic Product Management. Formerly President Nalge Nunc, a Fisher Scientific Company and President Bioprocess Production, Thermo Fisher Scientific, and Director of Marketing at Rubbermaid where he was also responsible for Consumer and International Marketing (Japan and Europe). His B. A. with Honors is from Princeton and his MBA from the University of Chicago.
Linda McAllister, MD. Ph.D., Vice President R&D and Chief Medical Officer. Formerly Assitant Clinical Professor of Medicine at UCSF and Attending Physician in the SFGH ER and UCSF; responsibility for patient care and staff supervision. She worked at Affymetrix, Celera and at Roche where she was Director of Technology Management. Most recently at Arbor Vita she was EVP & CMO, where she managed the FDA approval of devices for detecting influenza and cervical cancer/HPV. Her B.S. is from Caltech; M.D. from Stanford, and Ph.D. from Stanford University (Neuroscience Program, Dr. Corey Goodman in Molecular Genetics of Neuronal Development). Her Post-doctoral Fellowship at Stanford was in the lab of Dr. Patrick O. Brown, in Genetic Applications of DNA Microarrays.
Michael Royals, DVM, Chief Science Officer. Nearly 15 years designing and commercializing medical devices at B. Braun and Bio-Logistics Preclinical. Manages the company's global research and technology application collaborations. DVM from Colorado State University.
Philip Vorwald, Vice President Commercial Operations. Former Vice-President of Becton Dickinson Biosciences Europe with over 25 years of experience in sales, marketing and business development, and general management in biotech start ups. Manages all commercial aspects of product sales, marketing and customer support. BS from Catholic University and MS from Medical College of Virginia.
Tony Allard is President of Hearthstone Investments, which focuses on investing in Western Canada. He has practiced securities law in British Columbia and he holds a B.A. and L.L.B. from the University of Alberta.
Ann Arvin M.D. is the Lucile Salter Packard Professor of Pediatrics and Professor of Microbiology & Immunology, Stanford University School of Medicine. Her research laboratory investigates the varicella-zoster virus (VZV, chicken pox); her clinical research examines immunity in infants and young children in response to viral infections and vaccines, including influenza vaccines. She is a member of the Institute of Medicine and serves on the Board on Life Sciences of the NAS/NRC, the director’s Advisory Council of the NIH NIAID, and was a member of the Planning Group on Pandemic Influenza Research Gaps, IOM, 2005, the NIAID Blue Ribbon Panel on Influenza, 2006, and the working group on novel H1N1 of the President's Advisory Council on Science & Technology, 2009.
Kathy Callender, Founder. 35 years of experience in clinical health care, patient care and international medical social work. She teaches and trains nurses and health care workers and champions our mission around the world. BS from University of Missouri.
Kim Duncan is Principal of Kulik Investments, a private investment fund focused on early stage venture and private equity investments. Formerly Mr. Duncan was with Goldman Sachs and he holds a B.S. from Yale University.
Laurence Marton M.D. Formerly Dean of the University of Wisconsin-Madison Medical School and Chair of the Department of Laboratory Medicine at UCSF, where he was a Professor in the Departments of Laboratory Medicine and Neurological Surgery. He is Chief Scientific Officer of Progen Pharmaceuticals and previously held similar positions at Cellgate and SLIL Biomedical. He serves as a consultant for industry and for governmental and academic institutions and was appointed by the Governor of Wisconsin to the Wisconsin Technology Council.
Joel Palefsky M.D. Professor of Medicine. He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections. He is Director of the world's first clinic devoted to prevention of anal cancer, at UCSF. He is the chair of the HPV Working Group of the AIDS Malignancy Consortium and is co-director of the Cancer and Immunology Program of the UCSF Comprehensive Cancer Center.
Markus Pedriks. Investor. Operational leadership and entrepreneur in Europe and North America in health, media, telecommunications, entertainment and real estate. MBA from IMD, Lausanne and BA in Economics from McGill University, Montreal.
Heather Potters, Chairman. Investor. Nearly 20 years in Private Equity fund management and international investment. (BCEE; Enterprise Investors); hands-on role in international business development and fund raising. MBA from Wharton and B.A. in International Management from Claremont McKenna College.
Bill Rutter Ph.D. Chairman and CEO of Synergenics LLC, which provides strategic science and business advice to concept-stage biotechnology startups. Formerly Executive Chairman of Chiron, the company he co-founded in 1981. A member of the National Academy of Sciences and the American Academy of Arts and Sciences, he has published more than 380 scientific articles and holds more than 20 patents and patent applications. Served as chairman of the UCSF's department of biochemistry and biophysics from 1979 to 1982. During his tenure at UCSF, his lab made key contributions to the emerging disciplines of biotechnology and genetic engineering.
Linda Sonntag, Ph.D. Former CEO SyStemix (NYSE: NVS; acquired by Novartis), first publicly traded hematopoetic stem cell company, and General Partner at Axiom Venture Partners, investor in medical, healthcare, media and communications. PhD (University of Witwatersrand); post-doc at UCSF with Herb Boyer and visiting scientist at the Weizmann Institute.
Bruce Wintroub M.D. Professor and Chair of the Department of Dermatology and Vice Dean of the School of Medicine at UCSF. He has chaired the dermatology program for 25 years and has led the development of one of the outstanding clinical and scientific dermatology departments in the US. He is Chairman of the Dermatology Foundation and has trained many of today’s leaders in dermatology.
